Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Deffered Revenue (2016)

Rein Therapeutics filings provide 1 years of Non-Current Deffered Revenue readings, the most recent being $11000.0 for Q4 2016.

  • For the quarter ending Q4 2016, Non-Current Deffered Revenue changed N/A year-over-year to $11000.0, compared with a TTM value of $11000.0 through Dec 2016, changed N/A, and an annual FY2016 reading of $11000.0, changed N/A over the prior year.
  • Non-Current Deffered Revenue hit $11000.0 in Q4 2016 for Rein Therapeutics.
  • The five-year high for Non-Current Deffered Revenue was $11000.0 in Q4 2016, with the low at $11000.0 in Q4 2016.